Avidity Partners Management LP Avidity Biosciences, Inc. Transaction History

Avidity Partners Management LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$15.35 - $25.65 $30.8 Million - $51.5 Million	-2,009,455 Reduced 61.36%	1,265,545 $19.4 Million
Q4 2022 Feb 14, 2023	BUY	$10.06 - $22.66 $6.79 Million - $15.3 Million	675,000 Added 25.96%	3,275,000 $72.7 Million
Q3 2022 Nov 14, 2022	BUY	$15.46 - $23.43 $8.04 Million - $12.2 Million	519,800 Added 24.99%	2,600,000 $42.5 Million
Q2 2022 Aug 15, 2022	BUY	$11.18 - $20.5 $393,536 - $721,600	35,200 Added 1.72%	2,080,200 $30.2 Million
Q1 2022 May 16, 2022	BUY	$14.2 - $23.78 $3.27 Million - $5.47 Million	230,000 Added 12.67%	2,045,000 $37.8 Million
Q4 2021 Feb 14, 2022	BUY	$20.4 - $28.66 $3.47 Million - $4.87 Million	170,000 Added 10.33%	1,815,000 $43.1 Million
Q3 2021 Nov 15, 2021	BUY	$18.16 - $25.21 $29.9 Million - $41.5 Million	1,645,000 New	1,645,000 $40.5 Million
Q3 2020 Nov 16, 2020	SELL	$23.35 - $35.94 $5.48 Million - $8.44 Million	-234,814 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$26.62 - $31.5 $6.25 Million - $7.4 Million	234,814 New	234,814 $6.64 Million

251

107M

224K

161K

Ticker RNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,127,000
Market Cap $1.81B
Description
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

Stay updated on Avidity Partners Management LP with notifications on news.